BioLineRx Ltd.
BLRX
$3.22
$0.21797.26%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 84.79% | 62.03% | 30.42% | -52.71% | -142.93% |
| Total Depreciation and Amortization | 201.28% | 230.64% | 181.18% | 165.27% | 102.60% |
| Total Amortization of Deferred Charges | 1,157.63% | -- | -65.50% | -65.50% | -65.50% |
| Total Other Non-Cash Items | -182.01% | -139.68% | -104.02% | 1,029.77% | 739.11% |
| Change in Net Operating Assets | -243.55% | -481.66% | -394.12% | 210.38% | 1,127.71% |
| Cash from Operations | -94.06% | 9.04% | 5.35% | -0.11% | 13.84% |
| Capital Expenditure | 54.31% | 52.23% | 54.76% | 20.00% | 11.45% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 1,786.35% | -108.13% | -219.64% | 102.00% | -62.29% |
| Cash from Investing | 1,934.21% | -108.47% | -223.80% | 105.16% | -63.95% |
| Total Debt Issued | -- | 3,557.37% | 110.64% | -- | -- |
| Total Debt Repaid | -651.71% | -203.86% | -170.26% | -31.28% | 34.86% |
| Issuance of Common Stock | -2.85% | 308.82% | 60.39% | 18.66% | 18.66% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 37.21% | 1,155.41% | 74.64% | -33.38% | -26.33% |
| Foreign Exchange rate Adjustments | 109.82% | 111.16% | 74.04% | 88.32% | 63.10% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 197.62% | 120.62% | 87.65% | -29.24% | -163.50% |